Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421723 | 0.87 | MAPT (0.47) | MAPTTP53THRBLMNAGAA | |
| SCHEMBL6424028 | 0.76 | MAPT (0.43) | MAPTTP53THRBLMNAGAA | |
| SCHEMBL6420791 | 0.74 | MAPT (0.56) | MAPTTP53THRBLMNAGAA | |
| SCHEMBL6353752 | 0.74 | SCD (0.46) | MAPT | |
| SCHEMBL4832511 | 0.70 | POLB (0.47) | THRBLMNAPOLB | |
| SCHEMBL6346320 | 0.69 | RAB9A (0.35) | — | |
| SCHEMBL7142275 | 0.69 | ACHE (0.41) | MAPTTP53THRBLMNAPOLB | |
| Hydrochloric Acid SCHEMBL6420638 | 0.68 | KDM2B (0.40) | MAPTTHRBLMNAPOLB | |
| SCHEMBL6423206 | 0.67 | MAPT (0.57) | MAPTTP53LMNAGAAPOLB | |
| SCHEMBL4807003 | 0.67 | HSD17B10 (0.51) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | MAPT 4835/4885TP53 4473/4885THRB 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.